Cancer, treatment immunotoxins

The development of monoclonal antibodies (mAbs) has revolutionized cancer treatment, and several mAbs are today approved for clinical use. Treatment resistance is often a problem in mAbs-treatment where multiple treatment series are necessary [100]. Dmg response can be increased by binding mAbs to cytotoxic compounds, such as protein toxins, forming immunotoxins (ITs) [101]. The historical problems with first and second generation ITs are largely solved by the use of recombinant DNA technology where chimeric proteins consisting of the Fv-ffagment of an antibody and... 

Human parenteral toxicity for abrin is approximately 0.1-1 Jig/kg (Romano et al, 2007). However, based on clinical trials on abrin-immunotoxin use for cancer treatment, the human minimum lethal dose by intravenous injection was estimated to be >0.3 Jig/kg without occurrence of serious adverse effects (Gill, 1982). 

Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin Treatment of Cancer. Anna Rev Med 2007 58 221-37. 

---